Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

THERAPEUTIC APHERESIS - A US MARKET REPORT   

Research Abstract

This report analyzes the US market for Therapeutic Apheresis in US$ Thousand by the following procedures: Photopheresis, Plasmapheresis, Erythrocytapheresis, Plateletpheresis, Leukapheresis, and Lipidpheresis. The specific end-use segments analyzed are Neurology Disorders, Hematology & Oncology Disorders, Rheumatology Disorders, and Others. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for this market. The report profiles 10 companies including many key and niche players such as CaridianBCT, Inc., Fenwal, Inc., Fresenius Medical Care North America, Haemonetics Corporation, HemaCare Corporation, and Therakos, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1237
Price : $4500
Companies : 10
Pages : 126
Date : September 2011
Market Data Tables : 38
Status: * New Report

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  THERAPEUTIC APHERESIS (Complete Report) Pages : 126   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......15 $295  
   Study Reliability and Reporting Limitations.......1  
   Disclaimers.......2  
   Data Interpretation & Reporting Level.......3
Quantitative Techniques & Analytics.......3
Product Definitions and Scope of Study.......3
  
   Photopheresis.......4
Plasmapheresis.......4
Erythrocytapheresis.......4
Plateletpheresis.......4
Leukapheresis.......4
  
   Lipidpheresis.......5  
  2. MARKET OUTLOOK.......69 $950  
   Market Trends at a Glance.......61$100
   Current & Future Analysis.......7
Photopheresis: A Segment with High Growth Rate Owing to Increasing Demand in Off-label
  Indications.......7
1$100
   Plasmapheresis: The Method of Choice for Plasma Collection.......8
Table 1: Plasma Collection Methods: Percentage Breakdown by Fractionation and Extraction from Whole Blood (2000 Vs. 2010) (includes corresponding Graph/Chart).......8

Table 2: Leading Plasma Product Companies (2009): Market Share Breakdown for Baxter, CSL, Grifols/ Talecris, Biotest, and Others (includes corresponding Graph/Chart).......8
1$350
   Plateletpheresis Emerges as the Treatment of Choice.......9
Increase in Number of Platelet Donors Owing to Apheresis Procedure.......9
Pediatrics: An Unexplored Domain in Therapeutic Apheresis.......9
1$100
   Vendors’ Attitude Hampers Growth Prospects of Therapeutic Apheresis.......10
Technological Advancements and Novel Indications to Augur well for the Therapeutic
  Apheresis Market.......10
Lack of Awareness among Patients Restrains Market Growth.......10
1$100
   Challenges in the Therapeutic Apheresis Market.......11
Need to Develop Inexpensive Apheresis Therapies.......11
Scarcity of Qualified Donors.......11
Challenges in the Unexplored Pediatrics Segment.......11
Therapeutic Apheresis: An Overview of Regulatory Environment and Reimbursement
  Scenario.......11
1$100
   New Reimbursement Policies to Create Growth Opportunities for Therapeutic
  Apheresis.......12
Medicaid Coverage for Therapeutic Apheresis by Various Conditions.......12
2$200
   Table 3: APC* Payment Rates For Different Therapeutic Apheresis Procedures (2009-2010).......141$350
  3. COMPETITIVE SCENARIO.......154 $950  
   Japan-based Terumo Corp. Acquires CaridianBCT, the Leading Player in Therapeutic
  Apheresis Market.......15
1$100
   Market Share Trends.......16
Therapeutic Apheresis in Neurology Disorders: Market Shares by Revenues.......16
Table 4: US Market for Therapeutic Apheresis in Neurological Disorders (2010): Market Share Breakdown of Revenues by Company for Caridian BCT, Fresenius- Kabi LLC, Haemonetics, and Others (includes corresponding Graph/Chart).......16
1$350
   Therapeutic Apheresis in Neurology Disorders: Market Shares by Number of
  Procedures.......17
Table 5: US Market for Therapeutic Apheresis in Neurological Disorders (2010): Market Share Breakdown of Number of Procedures by Company for CaridianBCT, Fresenius-Kabi, Haemonetics, and Others (includes corresponding Graph/Chart).......17
Therapeutic Apheresis in Hematology and Oncology Disorders: Market Share by
  Revenues.......17
Table 6: US Market for Therapeutic Apheresis in Hematology and Oncology Disorders (2010): Market Share Breakdown of Revenues by Company for CaridianBCT, Therakos, Fresenius-Kabi, and Others (includes corresponding Graph/Chart).......17
1$350
   Therapeutic Apheresis in Hematology and Oncology Disorders: Market Share by Number of
  Procedures.......18
Table 7: US Market for Therapeutic Apheresis in Hematology and Oncology Disorders (2010): Market Share Breakdown of Number of Procedures by Company for CaridianBCT, Fresenius-Kabi, and Others (includes corresponding Graph/Chart).......18
1$350
  4. THERAPEUTIC APHERESIS: A SEGMENTAL OVERVIEW.......1919 $2450  
   Apheresis and Therapeutic Apheresis: The Difference.......19
Therapeutic Apheresis: An Introduction.......19
Applications of Therapeutic Apheresis.......19
2$200
   Emerging Applications of Therapeutic Apheresis.......21
Uses of Apheresis and Therapeutic Apheresis.......21
1$100
   Overview of Therapeutic Apheresis.......22
Blood Components.......22
Therapeutic Apheresis Process.......22
Duration, Frequency, and Efficiency of Therapeutic Apheresis.......22
1$100
   Segregation of Blood Components.......23
Centrifugation.......23
Filtration.......23
History of Therapeutic Apheresis Market.......23
1$100
   Therapeutic Apheresis Versus Dialysis.......24 1$100
   Table 8: Global Hemodialysis Market by Leading Players (2009): Market Share Breakdown for Fresenius Medical, Gambro, Baxter, and Others (includes corresponding Graph/Chart).......25
Categories of Indications for Therapeutic Apheresis.......25
Types of Therapeutic Apheresis Procedures.......25
1$350
   Photopheresis.......26
Functioning of THERAKOS™, a Typical Photopheresis System.......26
Plasmapheresis.......26
Plasma Exchange and Plasmapheresis: The Difference.......26
1$100
   Therapeutic Plasma Exchange (TPE) or Plasma Exchange.......27
TPE: Abnormal Components Removed from Blood.......27
Plasmapheresis: Potential Uses Discovered in the Early Years.......27
Potential Use of Plasmapheresis in Select Diseases Discovered in the Early
  Years.......27
1$100
   Erythrocytapheresis.......28
Plateletpheresis.......28
Leukapheresis.......28
Lipidpheresis.......28
Cytapheresis.......28
Therapeutic Apheresis is Remedial for Various Diseases.......28
1$100
   Cost of Select Therapeutic Apheresis Procedures: An Overview.......29
1. Photopheresis in GVHD (Graft-Versus-Host Disease).......29
2. Lipid Apheresis (LDL Apheresis).......29
1$100
   3. Plasmapheresis and Other Procedures.......30
Therapeutic Apheresis: What is the Risk Involved?.......30
1$100
   Replacement Fluid in Therapeutic Apheresis.......31
Replacement Fluids Used in Therapeutic Apheresis.......31
Various Replacement Fluids.......31
Select Replacement Fluids and their Limitations.......31
1$100
   Fluid Balance in Fluid Replacement.......32
Table 9: Volume Exchange of Plasma Constituents.......32

Table 10: Removal of IgM and IgG by Plasma Exchange Volume.......32

Table 11: Therapeutic Apheresis: Percentage Decrease and Restoration of Blood Components.......32
1$350
   Complications Involved and Suggested Treatment in the Therapeutic Apheresis
  Procedure.......33
1$100
   Therapeutic Plasmapheresis with Fresh Frozen Plasma (FFP) Replacement.......34
Sources of Blood Plasma.......34
Plasma Donations.......34
1$100
   Table 12: Number of Plasma Donation Centers in US and Europe: 2006-2008 (includes corresponding Graph/Chart).......35

Table 13: Number of Plasma Donations in US and Europe (In Thousands): 2006-2008 (includes corresponding Graph/Chart).......35
1$350
   Table 14: Number of Plasma Donations Required Annually by Disease Type in the US: 2009 (includes corresponding Graph/Chart).......36
Pre-requisites for Plasma Donors.......36
Select IQPP-authorized Plasma Collection Centers (US).......36
CFA – An Effective way to Pull Up Cold Hemagglutinin Disease.......36
1$350
   Trima Accel, the most Widely Used Platelet Collection Equipment in the US.......371$100
  5. PRODUCT AND TECHNOLOGICAL DEVELOPMENTS.......384 $295  
   Health Canada Licenses CaridianBCT’s new Protocol for Spectra Optia® Apheresis
  System.......38
Fenwal’s Amicus System Obtains CE Mark Certification for a Therapeutic Plasma Exchange
  Protocol.......38
CaridianBCT Releases Spectra Optia Apheresis System Version 5.......38
1$100
   CaridianBCT Introduces Trima Accel® Version 6.......39
CaridianBCT Introduces RBCX Protocol in Canada.......39
CaridianBCT Introduces Spectra Optia® System Mononuclear Cell Collection
  Protocol.......39
1$100
   Golden Meditech Company to Launch Model 3000H Plasma Exchange System.......40
HemoCleanse to Develop Novel Plasmapheresis Device.......40
Aethlon Develops a New Device to Remove HIV.......40
1$100
   Therapeutic Plasmapheresis for Treatment of Autoimmune Diseases.......411$100
  6. RECENT INDUSTRY ACTIVITY.......424 $295  
   Fenwal’s Amicus System Obtains CE Mark Certification for a Therapeutic Plasma Exchange
  Protocol.......42
Terumo Corp. Completes Acquisition of CaridianBCT .......42
Fenwal Obtains FDA Approval for Collection of InterSol® Preserved Platelets using
  Amicus® Cell Separator.......42
1$100
   FDA Clears Fenwal’s Software for Autopheresis-C® System.......43
HemaCare Inks Commercial Cell Therapy Collection Agreement with Dendreon.......43
Cerus Receives CE Mark Approval for the Latest Configuration of INTERCEPT Blood
  System.......43
1$100
   Therakos Obtains FDA Approval for THERAKOS™ CELLEX™ Photopheresis System.......44
Biotest Acquires Talecris’ Plasma Collection Unit.......44
CaridianBCT Receives CE Mark Approval for Expanded Mirasol Pathogen Reduction
  Technology System.......44
1$100
   Gambro Changes Name to CaridianBCT.......45
Therakos Obtains CE Mark for THERAKOS™ CELLEX™ Photopheresis System in Europe.......45
Verax Biomedical Gains CE Mark for Platelet PGD® Test.......45
1$100
  7. STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST.......469 $495  
   OccuLogix Puts Off Clinical Development of RHEO™ System.......46
Baxter Divests Transfusion Therapies Business.......46
1$100
   SCSG Gets Hold of Fresenius Medical Care Extracorporeal Alliance.......47
Rheologics Technologies Takes Over Cardiodyne Electronics.......47
Biotest Obtains Plasma and Protein Business Unit of Nabi BioPharmaceuticals.......47
Gambro BCT Receives FDA Clearance for Spectra Optia System.......47
MedaSorb Receives Rights for Blood Processing.......47
1$100
   Fresenius Medical Care Takes Over Renal Care.......48
Haemonetics Signs Acquisition Agreement with Arryx.......48
Cerus Receives Rights for INTERCEPT Blood System.......48
Blood Systems to Implement Gambro BCT 7-day platelets.......48
Renal Care Pockets Bay Area Mobile Apheresis Program.......48
1$100
   Haemonetics Pacts with FMCEA.......49
PhereSys and ACGT Ink Consulting Services Pact.......49
CHF Forges a Service Provider Pact with FMCEA.......49
Otsuka America Inks a Pact with HemaCare.......49
Gambro Acquires Ivex.......49
1$100
   Fresenius HemoCare Becomes a Part of Fresenius Kabi.......50
Alpha Therapeutic Sells Assets to Probitas Pharma and Baxter.......50
Gambro Signs Agreement with The American Red Cross.......50
Gambro Receives Contract from NBS.......50
FMC-EA Inks Deal with Allina Hospitals.......50
1$100
   Gambro Starts a New Company, Navigant Biotechnologies.......51
Gambro’s Vista™ Receives Approval from FDA.......51
Gambro’s New Anticoagulant Solution Receives FDA Approval.......51
Gambro BCT Receives FDA Clearance for New Filter Tubing Sets Developed by Pall.......51
1$100
   Gambro Launches Trima Accel Automated Blood Collection System.......52
Fresenius HemoCare Acquires PROSORBA® Column from Cypress Bioscience.......52
Gambro Buys the Assets of Sanguistech.......52
Haemonetics Inks Purchase Agreement with Alpha Therapeutic Corp.......52
Gambro Joins Forces with the Walter Reed Army Institute of Research.......52
1$100
   Gambro Collaborates with Dendreon for Commercialization of Therapeutic
  Vaccines.......53
Gambro AB Enters into a Partnership with Sangart.......53
WakeMed Awards a Contract to HemaCare’s Subsidiary.......53
HemaCare’s Subsidiary Coral in Agreement with CMH.......53
1$100
   BioTransplant Inks an Exclusive Distribution Agreement with Gambro BCT.......54
Gambro BCT Receives US Patent for its Pathogen Inactivation Technology.......54
Gambro’s Trima Receives Approval from The Japanese Red Cross Society.......54
Gambro BCT Test Launches the Vista™ Information System.......54
1$100
  8. FOCUS ON SELECT GLOBAL PLAYERS.......553 $295  
   CaridianBCT, Inc........55
CaridianBCT’s Product and Technological Innovations: 1988-2009.......55
1$100
   Fenwal, Inc........56
Fresenius Medical Care North America (FMCNA).......56
Haemonetics Corp........56
1$100
   HemaCare Corp........57
Therakos, Inc........57
1$100
  9. MARKET PERSPECTIVE.......58   
   Table 15: The US Recent Past, Current & Future Market Analysis for Therapeutic Apheresis by Procedure – Photopheresis, Plasmapheresis, Erythrocytapheresis, Leukapheresis, Lipidpheresis, and Plateletpheresis Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2017 (includes corresponding Graph/Chart).......581$350
   Table 16: The US Historic Review for Therapeutic Apheresis by Procedure – Photopheresis, Plasmapheresis, Erythrocytapheresis, Leukapheresis, Lipidpheresis, Immunoadsorption, and Plateletpheresis Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2003 through 2008 (includes corresponding Graph/Chart).......591$350
   Table 17: The US 15-Year Perspective for Therapeutic Apheresis by Procedure – Percentage Breakdown of Revenues for Photopheresis, Plasmapheresis, Erythrocytapheresis, Lipidpheresis, Plateletpheresis, Leukapheresis, and Immunoadsorption Markets Independently Analyzed for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......601$350
   Table 18: The US Recent Past, Current & Future Market Analysis for Therapeutic Apheresis by Disorder Type – Hematology and Oncology, Neurology, Rheumatology, and Other Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2009 through 2017 (includes corresponding Graph/Chart).......611$350
   Table 19: The US Historic Review for Therapeutic Apheresis by Disorder Type – Hematology and Oncology, Neurology, Rheumatology, and Other Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2003 through 2008 (includes corresponding Graph/Chart).......621$350
   Table 20: The US 15-Year Perspective for Therapeutic Apheresis by Disorder Type – Percentage Breakdown of Revenues for Hematology and Oncology, Neurology, Rheumatology, and Other Markets Independently Analyzed for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).......631$350
  10. APPENDIX.......64   
   Reported Uses of Therapeutic Apheresis.......641$100
COMPETITION 53$995
  
Total Companies Profiled: 10 (including Divisions/Subsidiaries - 11)

Region/Country                 Players


The United States                10   
Japan                             1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign